Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort

Neurology

Volumn 64, Issue 1, 2005, Pages 87-93

  Marras, C ^a,g   McDermott, M P ^e   Rochon, P A ^b,c   Tanner, C M ^f   Naglie, G ^a,c,d   Rudolph, A ^e   Lang, A E ^a  

^a TORONTO REHABILITATION INSTITUTE   (Canada)

^b Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f PARKINSON S INSTITUTE   (United States)

^g TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; SELEGILINE; TOCOPHEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; GAIT DISORDER; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; SURVIVAL;

EID: 11444266497     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148603.44618.19     Document Type: Article

References (38)

1. Fall P-A, Saleh A, Fredrickson M, Olsson J-E, Granerus A-K. Survival time, mortality and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-1316.
2. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney Multicentre Study of Parkinson's Disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-307.
3. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57:1687-1694.
4. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-1060.
5. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
6. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare, 1987:153-163.
7. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-325.
8. Haenszel W, Loveland DB, Sirken MG. Lung cancer mortality as related to residence and smoking histories. I. White males. JNCI 1962;28:947-1001.
9. Breslow NE, Day NE. Statistical methods in cancer research, vol 2. New York: Oxford University Press, 1987:406.
10. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109-120.
11. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson disease. N Engl J Med 1993;328:176-183.
12. Tibblin G. A population study of 50-year-old men - an analysis of the non-participation group. Acta Med Scand 1965;178:453-459.
13. Wilhelmsen L, Staffan L, Wedel H, Werko L. A comparison between participants and non-participants in a primary preventive trial. J Chronic Dis 1976;29:331-339.
14. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-118.
15. Hoehn MM. Parkinson's disease: progression and mortality. Adv Neurol 1987;45:457-461.
16. Zumstein H, Seigfried J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol 1976;14:321-328.
17. Clarke CE. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Psychiatry 1993;56:690-693.
18. Diamond SG, Markham CH. Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J Neural Transm 1976;38:259-269.
19. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46:1044-1050.
20. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
21. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JAO, Mutch WJ. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990;81:294-299.
22. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival: a population-based study. Arch Neurol 2000;57:507-512.
23. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990;40:763-766.
24. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976;33:333-338.
25. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson's disease in Olmstead County, Minnesota. Arch Neurol 2003;60:91-96.
26. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-299.
27. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited - clinical features, natural history and mortality. Mov Disord 1998;13:885-894.
28. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997;54:260-264.
29. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-1713.
30. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson's disease: a systematic review. Arch Neurol 2002;59:1724-1728.
31. Lees AJ for the Parkinson Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995;311:1602-1607.
32. Thorogood M, Armstrong B, Nichols T, Hollowell J. Mortality in people taking selegiline: observational study. Br Med J 1998;317:252-254.
33. Olanow CW, Myllyla W, Sotaniemi KA, et al. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998;51:825-830.
34. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Br Med J 1998;316:1191-1195.
35. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384-393.
36. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615-620.
37. Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology 1998;50:1637-1647.
38. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;68:434-440.